Markets 

UK COVID-19 trial finds no benefit of gout drug in hospitalised adults

FILE PHOTO: Health care workers transport a patient at the Royal London Hospital, as the spread of the coronavirus disease (COVID-19) continues, in London, Britain, January 26, 2021. REUTERS/Hannah McKay

(Reuters) – A large British trial has halted enrolments to test gout drug colchicine as a potential treatment for patients hospitalised with COVID-19, after a sub-study of the trial found that the medication did not have any effect on the patients.

An independent panel suggested pausing recruitment of volunteers in the colchicine arm of the trial based on a preliminary analysis, scientists involved in UK’s RECOVERY study said. The study is the world’s largest trial of treatments for hospitalised COVID-19 adults.

Source: Read Full Article

You May Also Like

Zoom shares rise as company raises earnings outlook ahead of hybrid workplace

Cathie Wood’s ARK Invest Sells for 6\/21

Central bank digital cash may unleash flood of new payments players, says BIS